| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:CKB_EIF2AK2 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: CKB_EIF2AK2 | KinaseFusionDB ID: KFG1309 | FusionGDB2.0 ID: KFG1309 | Hgene | Tgene | Gene symbol | CKB | EIF2AK2 | Gene ID | 1152 | 5610 | |
| Gene name | creatine kinase B | eukaryotic translation initiation factor 2 alpha kinase 2 | ||||||||||
| Synonyms | B-CK|BCK|CKBB|CPK-B|HEL-211|HEL-S-29 | DYT33|EIF2AK1|LEUDEN|PKR|PPP1R83|PRKR | ||||||||||
| Cytomap | 14q32.33 | 2p22.2 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | creatine kinase B-typebrain creatine kinasecreatine kinase B chaincreatine kinase braincreatine kinase brain-typecreatine phosphokinase B-typeepididymis luminal protein 211epididymis secretory protein Li 29 | interferon-induced, double-stranded RNA-activated protein kinaseP1/eIF-2A protein kinasedouble stranded RNA activated protein kinaseeIF-2A protein kinase 2interferon-inducible elF2alpha kinasep68 kinaseprotein kinase Rprotein kinase RNA-regulatedp | ||||||||||
| Modification date | 20240407 | 20240411 | ||||||||||
| UniProtAcc | P12277 | P19525 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000348956, | ENST00000233057, ENST00000395127, ENST00000405334, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: CKB [Title/Abstract] AND EIF2AK2 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CKB(103986004)-EIF2AK2(37342384), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | EIF2AK2 | GO:0006468 | protein phosphorylation | 19189853 |
| Tgene | EIF2AK2 | GO:0017148 | negative regulation of translation | 12882984 |
| Tgene | EIF2AK2 | GO:0035455 | response to interferon-alpha | 19840259 |
| Tgene | EIF2AK2 | GO:0046777 | protein autophosphorylation | 22801494 |
| Tgene | EIF2AK2 | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 15121867 |
| Tgene | EIF2AK2 | GO:0140374 | antiviral innate immune response | 22948139 |
| Kinase Fusion gene breakpoints across CKB (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across EIF2AK2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-DU-6404-01A | CKB | chr14 | 103986004 | EIF2AK2 | chr2 | 37342384 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:103986004/:37342384) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CKB | EIF2AK2 |
| FUNCTION: Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate) (PubMed:8186255). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa (Probable). Acts as a key regulator of adaptive thermogenesis as part of the futile creatine cycle: localizes to the mitochondria of thermogenic fat cells and acts by mediating phosphorylation of creatine to initiate a futile cycle of creatine phosphorylation and dephosphorylation (By similarity). During the futile creatine cycle, creatine and N-phosphocreatine are in a futile cycle, which dissipates the high energy charge of N-phosphocreatine as heat without performing any mechanical or chemical work (By similarity). {ECO:0000250|UniProtKB:Q04447, ECO:0000269|PubMed:8186255, ECO:0000305}. | FUNCTION: IFN-induced dsRNA-dependent serine/threonine-protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the innate immune response to viral infection (PubMed:18835251, PubMed:19507191, PubMed:19189853, PubMed:21123651, PubMed:21072047, PubMed:22948139, PubMed:23229543, PubMed:22381929). Inhibits viral replication via the integrated stress response (ISR): EIF2S1/eIF-2-alpha phosphorylation in response to viral infection converts EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, resulting to a shutdown of cellular and viral protein synthesis, while concomitantly initiating the preferential translation of ISR-specific mRNAs, such as the transcriptional activator ATF4 (PubMed:19189853, PubMed:21123651, PubMed:22948139, PubMed:23229543). Exerts its antiviral activity on a wide range of DNA and RNA viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1) (PubMed:11836380, PubMed:19189853, PubMed:20171114, PubMed:19840259, PubMed:21710204, PubMed:23115276, PubMed:23399035). Also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation: phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral protein US11 (PubMed:11836380, PubMed:22214662, PubMed:19229320). In addition to serine/threonine-protein kinase activity, also has tyrosine-protein kinase activity and phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its ubiquitination and proteasomal degradation (PubMed:20395957). Either as an adapter protein and/or via its kinase activity, can regulate various signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved in the expression of genes encoding pro-inflammatory cytokines and IFNs (PubMed:22948139, PubMed:23084476, PubMed:23372823). Activates the NF-kappa-B pathway via interaction with IKBKB and TRAF family of proteins and activates the p38 MAP kinase pathway via interaction with MAP2K6 (PubMed:10848580, PubMed:15121867, PubMed:15229216). Can act as both a positive and negative regulator of the insulin signaling pathway (ISP) (PubMed:20685959). Negatively regulates ISP by inducing the inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A which activates FOXO1, which in turn up-regulates the expression of insulin receptor substrate 2 (IRS2) (PubMed:20685959). Can regulate NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 and NLRC4 inflammasomes (PubMed:22801494). Plays a role in the regulation of the cytoskeleton by binding to gelsolin (GSN), sequestering the protein in an inactive conformation away from actin (By similarity). {ECO:0000250|UniProtKB:Q03963, ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380, ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853, ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191, ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114, ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959, ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651, ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494, ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035, ECO:0000269|PubMed:32197074}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of CKB_EIF2AK2 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| CKB | P12277 | human | BCAR1 | P56945 | Y327 | PLLREEtyDVPPAFA | |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | S242 | NQRKAKRsLAPRFDL | |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | S83 | NkEKkAVsPLLLttt | |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | T451 | kRtRSKGtLRyMsPE | Pkinase |
| EIF2AK2 | P19525 | human | CDK1 | P06493 | Y4 | ____MEDytkIEkIG | Pkinase |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | Y293 | HRIDGKTyVIKRVkY | Pkinase |
| EIF2AK2 | P19525 | human | MAPT | P10636-8 | S262 | NVKskIGstENLkHQ | Tubulin-binding |
| EIF2AK2 | P19525 | human | KDM4C | Q9H3R0 | S918 | MFDDGsFsRDTFPED | |
| EIF2AK2 | P19525 | human | TP53 | P04637 | S392 | FktEGPDsD______ | |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | T446 | LkNDGkRtRSKGtLR | Pkinase |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | S6 | __MAGDLsAGFFMEE | |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | Y162 | QLAAkLAyLQILSEE | dsrm |
| EIF2AK2 | P19525 | human | EIF2S1 | P05198 | S49 | IEGMILLsELsRRRI | S1 |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | T255 | DLPDMkEtKytVDKR | |
| EIF2AK2 | P19525 | human | MAPT | P10636-8 | S356 | rVQskIGsLDNItHV | Tubulin-binding |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | T89 | VsPLLLtttNssEGL | |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | T88 | AVsPLLLtttNssEG | |
| EIF2AK2 | P19525 | human | PPP2R5A | Q15172 | S28 | VDGFTRKsVRKAQRQ | |
| EIF2AK2 | P19525 | human | TRIM28 | Q13263 | S473 | sGVkRsRsGEGEVsG | |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | T90 | sPLLLtttNssEGLs | |
| EIF2AK2 | P19525 | human | EIF2S1 | P05198 | S52 | MILLsELsRRRIRsI | S1 |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | Y101 | EGLsMGNyIGLINRI | dsrm |
| EIF2AK2 | P19525 | human | EIF2AK2 | P19525 | T258 | DMkEtKytVDKRFGM |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| CKB | ID | Description | 0.00e+00 |
| CKB | GO:0086100 | endothelin receptor signaling pathway | 9.30e-03 |
| CKB | GO:0048012 | hepatocyte growth factor receptor signaling pathway | 9.30e-03 |
| CKB | GO:0035729 | cellular response to hepatocyte growth factor stimulus | 9.30e-03 |
| CKB | GO:0035728 | response to hepatocyte growth factor | 9.30e-03 |
| CKB | GO:0048011 | neurotrophin TRK receptor signaling pathway | 1.03e-02 |
| CKB | GO:0038179 | neurotrophin signaling pathway | 1.34e-02 |
| CKB | GO:0048008 | platelet-derived growth factor receptor signaling pathway | 1.58e-02 |
| CKB | GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 1.58e-02 |
| CKB | GO:0050853 | B cell receptor signaling pathway | 1.77e-02 |
| CKB | GO:0007173 | epidermal growth factor receptor signaling pathway | 1.92e-02 |
| CKB | GO:0007229 | integrin-mediated signaling pathway | 1.92e-02 |
| CKB | GO:0038127 | ERBB signaling pathway | 1.92e-02 |
| CKB | GO:0008286 | insulin receptor signaling pathway | 1.92e-02 |
| CKB | GO:0010595 | positive regulation of endothelial cell migration | 1.92e-02 |
| CKB | GO:0050852 | T cell receptor signaling pathway | 1.98e-02 |
| CKB | GO:0010634 | positive regulation of epithelial cell migration | 2.27e-02 |
| CKB | GO:0050851 | antigen receptor-mediated signaling pathway | 2.37e-02 |
| CKB | GO:0032869 | cellular response to insulin stimulus | 2.37e-02 |
| CKB | GO:0010594 | regulation of endothelial cell migration | 2.51e-02 |
| CKB | GO:0032868 | response to insulin | 2.62e-02 |
| CKB | GO:0043542 | endothelial cell migration | 2.62e-02 |
| CKB | GO:0010632 | regulation of epithelial cell migration | 2.62e-02 |
| CKB | GO:0071375 | cellular response to peptide hormone stimulus | 2.62e-02 |
| CKB | GO:0002429 | immune response-activating cell surface receptor signaling pathway | 2.62e-02 |
| CKB | GO:0060326 | cell chemotaxis | 2.62e-02 |
| CKB | GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 2.62e-02 |
| CKB | GO:0010631 | epithelial cell migration | 2.62e-02 |
| CKB | GO:1901653 | cellular response to peptide | 2.62e-02 |
| CKB | GO:0090132 | epithelium migration | 2.62e-02 |
| CKB | GO:0090130 | tissue migration | 2.62e-02 |
| CKB | GO:0001558 | regulation of cell growth | 2.65e-02 |
| CKB | GO:0043434 | response to peptide hormone | 2.65e-02 |
| CKB | GO:0007015 | actin filament organization | 2.65e-02 |
| CKB | GO:0006935 | chemotaxis | 2.65e-02 |
| CKB | GO:0042330 | taxis | 2.65e-02 |
| CKB | GO:0002757 | immune response-activating signaling pathway | 2.65e-02 |
| CKB | GO:0001667 | ameboidal-type cell migration | 2.65e-02 |
| CKB | GO:0016049 | cell growth | 2.65e-02 |
| CKB | GO:0002764 | immune response-regulating signaling pathway | 2.65e-02 |
| EIF2AK2 | ID | Description | 0.00e+00 |
| EIF2AK2 | GO:0034599 | cellular response to oxidative stress | 1.67e-03 |
| EIF2AK2 | GO:0062197 | cellular response to chemical stress | 1.98e-03 |
| EIF2AK2 | GO:0006979 | response to oxidative stress | 3.31e-03 |
| EIF2AK2 | GO:0016032 | viral process | 3.36e-03 |
| EIF2AK2 | GO:0072594 | establishment of protein localization to organelle | 3.42e-03 |
| EIF2AK2 | GO:0006606 | protein import into nucleus | 3.95e-03 |
| EIF2AK2 | GO:0051170 | import into nucleus | 3.95e-03 |
| EIF2AK2 | GO:0009267 | cellular response to starvation | 4.33e-03 |
| EIF2AK2 | GO:0034063 | stress granule assembly | 5.56e-03 |
Top |
Related Drugs to CKB_EIF2AK2 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning CKB-EIF2AK2 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to CKB_EIF2AK2 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |